Are you over 18 and want to see adult content?
More Annotations
![A complete backup of clickfrenzy.com.au](https://www.archivebay.com/archive2/9eeeb6da-e92b-46c3-87d3-f0ca634b02a5.png)
A complete backup of clickfrenzy.com.au
Are you over 18 and want to see adult content?
![A complete backup of imas-cinderella.com](https://www.archivebay.com/archive2/aa80ee75-636f-49f3-acc1-2d2e468bc0f8.png)
A complete backup of imas-cinderella.com
Are you over 18 and want to see adult content?
![A complete backup of zoeksollicitant.be](https://www.archivebay.com/archive2/7c77d788-3d6c-4537-8551-04505624fa4e.png)
A complete backup of zoeksollicitant.be
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of www.liberoquotidiano.it/news/spettacoli/13564302/grande-fratello-vip-paola-di-benedetto-federico-fidanzato-](https://www.archivebay.com/archive2/d76a3992-dbef-45ee-8f01-bdc50fa5a29b.png)
A complete backup of www.liberoquotidiano.it/news/spettacoli/13564302/grande-fratello-vip-paola-di-benedetto-federico-fidanzato-
Are you over 18 and want to see adult content?
![A complete backup of www.augsburger-allgemeine.de/sport/Fortuna-Duesseldorf-Gladbach-heute-im-Live-TV-Stream-Ticker-Uebertragung](https://www.archivebay.com/archive2/6f840975-0784-4131-a7d2-40234ff4fc16.png)
A complete backup of www.augsburger-allgemeine.de/sport/Fortuna-Duesseldorf-Gladbach-heute-im-Live-TV-Stream-Ticker-Uebertragung
Are you over 18 and want to see adult content?
Text
Pharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. Ms. Moukheibir most recently served as chief executive officer of MedDay Pharmaceuticals, or MedDay, a biopharmaceutical company that focused on nervous system disorders, from July 2019 to January 2021. She was also the chairman of the board of directors of IRONWOOD PHARMACEUTICALS, INC. Investor Emails Alerts. RSS Feeds. Home › Investors › Financial Information › Annual Reports. NASDAQ: IRWD 11.56-0.01 -0.09% Volume: 1,989,061 June 1, 2021 4:00 PM Pricing delayed by 20 minutes Click tolearn more.
IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. Press Releases. Investor Contacts. Investor Emails Alerts. RSS Feeds. Home › Investors › Events & Presentations. NASDAQ: IRWD 11.75+0.19 1.64% Volume: 220,027 June 2, 2021 10:05 AM Pricing delayed by 20 minutes Click to learn more. HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. Ms. Moukheibir most recently served as chief executive officer of MedDay Pharmaceuticals, or MedDay, a biopharmaceutical company that focused on nervous system disorders, from July 2019 to January 2021. She was also the chairman of the board of directors of IRONWOOD PHARMACEUTICALS, INC. Investor Emails Alerts. RSS Feeds. Home › Investors › Financial Information › Annual Reports. NASDAQ: IRWD 11.56-0.01 -0.09% Volume: 1,989,061 June 1, 2021 4:00 PM Pricing delayed by 20 minutes Click tolearn more.
IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. Press Releases. Investor Contacts. Investor Emails Alerts. RSS Feeds. Home › Investors › Events & Presentations. NASDAQ: IRWD 11.75+0.19 1.64% Volume: 220,027 June 2, 2021 10:05 AM Pricing delayed by 20 minutes Click to learn more. HOME - IRONWOOD PHARMACEUTICALS Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – Thomas McCourt named permanent CEO and appointed to Ironwood Board of Directors – – Gina Consylman to step down as SVP, CFO effective July 2, 2021 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $150 million of its outstanding shares of common stock through December 2022. “Ironwood maintains a disciplined and thoughtful approach to capital allocation and IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or nearly 35% of current workforce – – Expects total cost savings of greater than $95 million, excluding anticipated one-time costsTHOMAS MCCOURT
Tom McCourt joined Ironwood in 2009. Mr. McCourt has served as our president since April 2019 and, prior to April 2019, had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at IRONWOOD PHARMACEUTICALS, INC. – Ironwood capitalizing on GI leadership and expertise in an effort to bring innovative therapies to patients – – Strategy centered on accelerating LINZESS ® (linaclotide) growth and advancing late-stage programs IW-3718 and MD-7246 – – Business poised to drive revenue growth and begin generating profits – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare IRONWOOD PHARMACEUTICALS, INC. Allergan plc ( NYSE : AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) today announced that Allergan has acquired rights to CONSTELLA ® (linaclotide) in the European Union , Switzerland , Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS ® (linaclotide) in IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). With a standard 10-month review timeline, the FDA Prescription Drug IRONWOOD PHARMACEUTICALS, INC. Constella® (linaclotide) is the first and only medicine approved by the European Commission for the symptomatic treatment of moderate to severe IBS-C in adults, that improves abdominal pain/discomfort, bloating and constipation First launches in Europe are expected in the first half of 2013 IBS-C is a functional gastrointestinal disorder affecting approximately 15 million adults HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. Investor Emails Alerts. RSS Feeds. Home › Investors › Financial Information › Annual Reports. NASDAQ: IRWD 11.56-0.01 -0.09% Volume: 1,989,061 June 1, 2021 4:00 PM Pricing delayed by 20 minutes Click tolearn more.
IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required:JULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to IRONWOOD PHARMACEUTICALS, INC. CAMBRIDGE, Mass. -(BUSINESS WIRE)-Jan. 15, 2019- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS® (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) in China . Ironwood anticipates that it HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. Investor Emails Alerts. RSS Feeds. Home › Investors › Financial Information › Annual Reports. NASDAQ: IRWD 11.56-0.01 -0.09% Volume: 1,989,061 June 1, 2021 4:00 PM Pricing delayed by 20 minutes Click tolearn more.
IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required:JULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to IRONWOOD PHARMACEUTICALS, INC. CAMBRIDGE, Mass. -(BUSINESS WIRE)-Jan. 15, 2019- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS® (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) in China . Ironwood anticipates that it HOME - IRONWOOD PHARMACEUTICALS Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or nearly 35% of current workforce – – Expects total cost savings of greater than $95 million, excluding anticipated one-time costs IRONWOOD PHARMACEUTICALS, INC. – Data showed improvement in both heartburn and regurgitation symptoms and further demonstrated the role of bile acid in refractory gastroesophageal reflux disease (GERD) – – IW-3718 is currently in two Phase III trials; top line data targeted for second half of 2020 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law.THOMAS MCCOURT
Tom McCourt joined Ironwood in 2009. Mr. McCourt has served as our president since April 2019 and, prior to April 2019, had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at MICHAEL SHETZLINE, M.D., PH.D. Michael Shetzline joined Ironwood in 2019. Dr. Shetzline has served as our chief medical officer, senior vice president and head of drug development since January 2019. Dr. Shetzline is a gastroenterologist and internist, with more than 25 years of experience in the biopharmaceutical industry and academia. Before joining Ironwood, Dr. Shetzline was vice president and JON DUANE - IRONWOOD PHARMACEUTICALS Jon Duane joined our board of directors in April 2019. Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm’s biotech practice. InJULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to IRONWOOD PHARMACEUTICALS, INC. Allergan plc ( NYSE : AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) today announced that Allergan has acquired rights to CONSTELLA ® (linaclotide) in the European Union , Switzerland , Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS ® (linaclotide) in HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. Investor Emails Alerts. RSS Feeds. Home › Investors › Financial Information › Annual Reports. NASDAQ: IRWD 11.56-0.01 -0.09% Volume: 1,989,061 June 1, 2021 4:00 PM Pricing delayed by 20 minutes Click tolearn more.
IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patentTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required:JULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. Investor Emails Alerts. RSS Feeds. Home › Investors › Financial Information › Annual Reports. NASDAQ: IRWD 11.56-0.01 -0.09% Volume: 1,989,061 June 1, 2021 4:00 PM Pricing delayed by 20 minutes Click tolearn more.
IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patentTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required:JULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to HOME - IRONWOOD PHARMACEUTICALS Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or nearly 35% of current workforce – – Expects total cost savings of greater than $95 million, excluding anticipated one-time costs IRONWOOD PHARMACEUTICALS, INC. – Data showed improvement in both heartburn and regurgitation symptoms and further demonstrated the role of bile acid in refractory gastroesophageal reflux disease (GERD) – – IW-3718 is currently in two Phase III trials; top line data targeted for second half of 2020 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelTHOMAS MCCOURT
Tom McCourt joined Ironwood in 2009. Mr. McCourt has served as our president since April 2019 and, prior to April 2019, had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab atTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. MICHAEL SHETZLINE, M.D., PH.D. Michael Shetzline joined Ironwood in 2019. Dr. Shetzline has served as our chief medical officer, senior vice president and head of drug development since January 2019. Dr. Shetzline is a gastroenterologist and internist, with more than 25 years of experience in the biopharmaceutical industry and academia. Before joining Ironwood, Dr. Shetzline was vice president andJULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to JON DUANE - IRONWOOD PHARMACEUTICALS Jon Duane joined our board of directors in April 2019. Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm’s biotech practice. In IRONWOOD PHARMACEUTICALS, INC. Allergan plc ( NYSE : AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) today announced that Allergan has acquired rights to CONSTELLA ® (linaclotide) in the European Union , Switzerland , Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS ® (linaclotide) in HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021. May 6, 2021. Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program. May 6, 2021. Ironwood Pharmaceuticals Reports First Quarter 2021 Results. April 22, 2021. IRONWOOD PHARMACEUTICALS, INC. Investor Emails Alerts. RSS Feeds. Home › Investors › Financial Information › Annual Reports. NASDAQ: IRWD 11.56-0.01 -0.09% Volume: 1,989,061 June 1, 2021 4:00 PM Pricing delayed by 20 minutes Click tolearn more.
IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. Press Releases. Investor Contacts. Investor Emails Alerts. RSS Feeds. Home › Investors › Events & Presentations. NASDAQ: IRWD 11.75+0.19 1.64% Volume: 220,027 June 2, 2021 10:05 AM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowel HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021. May 6, 2021. Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program. May 6, 2021. Ironwood Pharmaceuticals Reports First Quarter 2021 Results. April 22, 2021. IRONWOOD PHARMACEUTICALS, INC. Investor Emails Alerts. RSS Feeds. Home › Investors › Financial Information › Annual Reports. NASDAQ: IRWD 11.56-0.01 -0.09% Volume: 1,989,061 June 1, 2021 4:00 PM Pricing delayed by 20 minutes Click tolearn more.
IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. Press Releases. Investor Contacts. Investor Emails Alerts. RSS Feeds. Home › Investors › Events & Presentations. NASDAQ: IRWD 11.75+0.19 1.64% Volume: 220,027 June 2, 2021 10:05 AM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelOUR PRODUCT
Linzess® (linaclotide) capsules for oral use. Please see full LINZESS Prescribing Information below and a website dedicated to providing you with product-specific information. In order to monitor the safety of our product, we encourage reporting any side effects experienced while taking LINZESS to AbbVie at IRONWOOD PHARMACEUTICALS, INC. – Thomas McCourt named permanent CEO and appointed to Ironwood Board of Directors – – Gina Consylman to step down as SVP, CFO effective July 2, 2021 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. Press Releases. Investor Contacts. Investor Emails Alerts. RSS Feeds. Home › Investors › Events & Presentations. NASDAQ: IRWD 11.75+0.19 1.64% Volume: 220,027 June 2, 2021 10:05 AM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $150 million of its outstanding shares of common stock through December 2022. “Ironwood maintains a disciplined and thoughtful approach to capital allocation and IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million. July 23, 2020. Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call. July 21, 2020. IRONWOOD PHARMACEUTICALS REPORTS FIRST QUARTER 2021 RESULTS Ironwood Pharmaceuticals Reports First Quarter 2021 Results. – LINZESS® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year –. –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million –. – GAAP net income of $40 million and IRONWOOD PHARMACEUTICALS, INC. – Ironwood also presented results of a separate survey of nearly 90,000 Americans that highlights the prevalence and burden of multiple GI diseases – – Preclinical data presented at DDW highlight linaclotide’s effect on visceral hypersensitivity, which plays a key role in IBS-C – - Ironwood’s DDW presentations feature four posters of distinction – Ironwood Pharmaceuticals, Inc IRONWOOD PHARMACEUTICALS, INC. Jan. 2, 2019- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. (NASDAQ: MYL) resolving patent litigations brought in response to Mylan’s abbreviated new drug applications (ANDAs) seeking approval to market generic versions of LINZESS (linaclotide) prior to the IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). With a standard 10-month review timeline, the FDA Prescription Drug HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required: HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required: HOME - IRONWOOD PHARMACEUTICALS Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – Thomas McCourt named permanent CEO and appointed to Ironwood Board of Directors – – Gina Consylman to step down as SVP, CFO effective July 2, 2021 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. – Presentations feature four posters of distinction – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present seven posters – four of which have been named posters of distinction – during the Digestive Disease Week ® (DDW) 2021 virtual meeting being held from May 21 through May 23, IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or nearly 35% of current workforce – – Expects total cost savings of greater than $95 million, excluding anticipated one-time costs MICHAEL SHETZLINE, M.D., PH.D. Michael Shetzline joined Ironwood in 2019. Dr. Shetzline has served as our chief medical officer, senior vice president and head of drug development since January 2019. Dr. Shetzline is a gastroenterologist and internist, with more than 25 years of experience in the biopharmaceutical industry and academia. Before joining Ironwood, Dr. Shetzline was vice president and JON DUANE - IRONWOOD PHARMACEUTICALS Jon Duane joined our board of directors in April 2019. Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm’s biotech practice. InJULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to IRONWOOD PHARMACEUTICALS, INC. Allergan plc ( NYSE : AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) today announced that Allergan has acquired rights to CONSTELLA ® (linaclotide) in the European Union , Switzerland , Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS ® (linaclotide) in HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required: HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required: HOME - IRONWOOD PHARMACEUTICALS Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – Thomas McCourt named permanent CEO and appointed to Ironwood Board of Directors – – Gina Consylman to step down as SVP, CFO effective July 2, 2021 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. – Presentations feature four posters of distinction – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present seven posters – four of which have been named posters of distinction – during the Digestive Disease Week ® (DDW) 2021 virtual meeting being held from May 21 through May 23, IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or nearly 35% of current workforce – – Expects total cost savings of greater than $95 million, excluding anticipated one-time costs MICHAEL SHETZLINE, M.D., PH.D. Michael Shetzline joined Ironwood in 2019. Dr. Shetzline has served as our chief medical officer, senior vice president and head of drug development since January 2019. Dr. Shetzline is a gastroenterologist and internist, with more than 25 years of experience in the biopharmaceutical industry and academia. Before joining Ironwood, Dr. Shetzline was vice president and JON DUANE - IRONWOOD PHARMACEUTICALS Jon Duane joined our board of directors in April 2019. Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm’s biotech practice. InJULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to IRONWOOD PHARMACEUTICALS, INC. Allergan plc ( NYSE : AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) today announced that Allergan has acquired rights to CONSTELLA ® (linaclotide) in the European Union , Switzerland , Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS ® (linaclotide) in HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required: HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more. IRONWOOD PHARMACEUTICALS, INC. – LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue – – 2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvements in abdominal pain relative to placebo – – Companies plan to discontinue development of MD-7246 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowelTERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. DEAR PROSPECTIVE FELLOW Application Information Eligibility: • andidates must have a Doctor of Pharmacy 'PharmD degree from an accredited college or university before the start of the fellowship term. • andidates must be authorized in the U.S. on a permanent basis without requiring sponsorship Application Process: • IPhO’s Fellow Match is the initial application portal and the following are required: HOME - IRONWOOD PHARMACEUTICALS Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
IRONWOOD PHARMACEUTICALS, INC. – Thomas McCourt named permanent CEO and appointed to Ironwood Board of Directors – – Gina Consylman to step down as SVP, CFO effective July 2, 2021 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a IRONWOOD PHARMACEUTICALS, INC. – Presentations feature four posters of distinction – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present seven posters – four of which have been named posters of distinction – during the Digestive Disease Week ® (DDW) 2021 virtual meeting being held from May 21 through May 23, IRONWOOD PHARMACEUTICALS, INC. – Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or nearly 35% of current workforce – – Expects total cost savings of greater than $95 million, excluding anticipated one-time costs MICHAEL SHETZLINE, M.D., PH.D. Michael Shetzline joined Ironwood in 2019. Dr. Shetzline has served as our chief medical officer, senior vice president and head of drug development since January 2019. Dr. Shetzline is a gastroenterologist and internist, with more than 25 years of experience in the biopharmaceutical industry and academia. Before joining Ironwood, Dr. Shetzline was vice president and JON DUANE - IRONWOOD PHARMACEUTICALS Jon Duane joined our board of directors in April 2019. Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm’s biotech practice. InJULIE MCHUGH
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to IRONWOOD PHARMACEUTICALS, INC. Allergan plc ( NYSE : AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) today announced that Allergan has acquired rights to CONSTELLA ® (linaclotide) in the European Union , Switzerland , Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS ® (linaclotide) in HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
OUR PRODUCT
Linzess® (linaclotide) capsules for oral use. Please see full LINZESS Prescribing Information below and a website dedicated to providing you with product-specific information. In order to monitor the safety of our product, we encourage reporting any side effects experienced while taking LINZESS to AbbVie at PATIENTS - IRONWOOD PHARMACEUTICALS Data generated in our clinical studies, and insights we receive from our scientists, physicians conducting our studies, and patient reported outcomes help drive our decision making. We register all interventional trials conducted in patients, prior to study initiation on www.clinicaltrials.gov, and comply with other clinical trialdisclosure
IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more.OUR PIPELINE
Partnering Opportunities. As a GI focused, US healthcare company, we are interested in discussing opportunities to collaborate on GI products. We are also seeking partners in territories outside of the US for select current development programs. Please contact us with more details on your area of interest.OUR EXECUTIVE TEAM
Our Executive Team. Our Board of Directors. Open Payments and Transparency. Our senior leaders bring a powerful combination of proven commercial, strategic and scientific capabilities. Our Values. Our Executive Team. Our Board of Directors. IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
OUR PRODUCT
Linzess® (linaclotide) capsules for oral use. Please see full LINZESS Prescribing Information below and a website dedicated to providing you with product-specific information. In order to monitor the safety of our product, we encourage reporting any side effects experienced while taking LINZESS to AbbVie at PATIENTS - IRONWOOD PHARMACEUTICALS Data generated in our clinical studies, and insights we receive from our scientists, physicians conducting our studies, and patient reported outcomes help drive our decision making. We register all interventional trials conducted in patients, prior to study initiation on www.clinicaltrials.gov, and comply with other clinical trialdisclosure
IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more.OUR PIPELINE
Partnering Opportunities. As a GI focused, US healthcare company, we are interested in discussing opportunities to collaborate on GI products. We are also seeking partners in territories outside of the US for select current development programs. Please contact us with more details on your area of interest.OUR EXECUTIVE TEAM
Our Executive Team. Our Board of Directors. Open Payments and Transparency. Our senior leaders bring a powerful combination of proven commercial, strategic and scientific capabilities. Our Values. Our Executive Team. Our Board of Directors. IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patentOUR PRODUCT
Linzess® (linaclotide) capsules for oral use. Please see full LINZESS Prescribing Information below and a website dedicated to providing you with product-specific information. In order to monitor the safety of our product, we encourage reporting any side effects experienced while taking LINZESS to AbbVie at PATIENTS - IRONWOOD PHARMACEUTICALS Data generated in our clinical studies, and insights we receive from our scientists, physicians conducting our studies, and patient reported outcomes help drive our decision making. We register all interventional trials conducted in patients, prior to study initiation on www.clinicaltrials.gov, and comply with other clinical trialdisclosure
OUR PIPELINE
We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. For more information, including how to adjust your cookie settings, please see our Cookie Policy.By continuing to navigate our website, you consent to the use of cookies.OUR COMPANY
We believe we have what it takes to achieve our vision and we’re all in. Together, we’re paving a path to long-term success. I am excited about the opportunity to be GI-focused and to bring exciting new therapies to our trusted GI community.”. Everyone at Ironwood is a true owner of the company. OUR BOARD OF DIRECTORS We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. For more information, including how to adjust your cookie settings, please see our Cookie Policy.By continuing to navigate our website, you consent to the use of cookies. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a OPEN PAYMENTS AND TRANSPARENCY The CMS Open Payments Customer Support Line Help Desk is also accessible via email at openpayments@cms.hhs.gov and via phone at 1-855-326-8366 (Monday through Friday, from 8:30 a.m. to 7:30 p.m. (ET), excluding federal holidays). Our Values. IRONWOOD PHARMACEUTICALS, INC. Investor Contacts. Investor Emails Alerts. RSS Feeds. Home › Investors › Events & Presentations. NASDAQ: IRWD 12.48+0.05 0.40% Volume: 116,678 May 21, 2021 09:45 AM Pricing delayed by 20 minutes Click to learn more.TERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Ironwood Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Ironwood Pharmaceuticals, Inc. or its management. HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
OUR PRODUCT
Linzess® (linaclotide) capsules for oral use. Please see full LINZESS Prescribing Information below and a website dedicated to providing you with product-specific information. In order to monitor the safety of our product, we encourage reporting any side effects experienced while taking LINZESS to AbbVie at PATIENTS - IRONWOOD PHARMACEUTICALS Data generated in our clinical studies, and insights we receive from our scientists, physicians conducting our studies, and patient reported outcomes help drive our decision making. We register all interventional trials conducted in patients, prior to study initiation on www.clinicaltrials.gov, and comply with other clinical trialdisclosure
IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more.OUR PIPELINE
Partnering Opportunities. As a GI focused, US healthcare company, we are interested in discussing opportunities to collaborate on GI products. We are also seeking partners in territories outside of the US for select current development programs. Please contact us with more details on your area of interest.OUR EXECUTIVE TEAM
Our Executive Team. Our Board of Directors. Open Payments and Transparency. Our senior leaders bring a powerful combination of proven commercial, strategic and scientific capabilities. Our Values. Our Executive Team. Our Board of Directors. IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent HOME - IRONWOOD PHARMACEUTICALSOUR COMPANYOUR PRODUCTOUR PIPELINEPARTNERSHIPSPATIENTSJOIN US Ironwood is a healthcare company dedicated to making a difference for people living with gastrointestinal (GI) diseasesIronwoodPharmaceuticals.
OUR PRODUCT
Linzess® (linaclotide) capsules for oral use. Please see full LINZESS Prescribing Information below and a website dedicated to providing you with product-specific information. In order to monitor the safety of our product, we encourage reporting any side effects experienced while taking LINZESS to AbbVie at PATIENTS - IRONWOOD PHARMACEUTICALS Data generated in our clinical studies, and insights we receive from our scientists, physicians conducting our studies, and patient reported outcomes help drive our decision making. We register all interventional trials conducted in patients, prior to study initiation on www.clinicaltrials.gov, and comply with other clinical trialdisclosure
IRONWOOD PHARMACEUTICALS, INC. Corporate Overview. At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. IRONWOOD PHARMACEUTICALS, INC. Home › Investors › Financial Information › SEC Filings. NASDAQ: IRWD 12.32-0.11 -0.89% Volume: 1,314,291 May 21, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more.OUR PIPELINE
Partnering Opportunities. As a GI focused, US healthcare company, we are interested in discussing opportunities to collaborate on GI products. We are also seeking partners in territories outside of the US for select current development programs. Please contact us with more details on your area of interest.OUR EXECUTIVE TEAM
Our Executive Team. Our Board of Directors. Open Payments and Transparency. Our senior leaders bring a powerful combination of proven commercial, strategic and scientific capabilities. Our Values. Our Executive Team. Our Board of Directors. IRONWOOD PHARMACEUTICALS, INC. 2021 2020 2019 2018 2017 2016. February 19, 2021. Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences. February 17, 2021. Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance. February 8,2021.
IRONWOOD PHARMACEUTICALS, INC. At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. IRONWOOD PHARMACEUTICALS, INC. – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patentOUR PRODUCT
Linzess® (linaclotide) capsules for oral use. Please see full LINZESS Prescribing Information below and a website dedicated to providing you with product-specific information. In order to monitor the safety of our product, we encourage reporting any side effects experienced while taking LINZESS to AbbVie at PATIENTS - IRONWOOD PHARMACEUTICALS Data generated in our clinical studies, and insights we receive from our scientists, physicians conducting our studies, and patient reported outcomes help drive our decision making. We register all interventional trials conducted in patients, prior to study initiation on www.clinicaltrials.gov, and comply with other clinical trialdisclosure
OUR PIPELINE
We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. For more information, including how to adjust your cookie settings, please see our Cookie Policy.By continuing to navigate our website, you consent to the use of cookies.OUR COMPANY
We believe we have what it takes to achieve our vision and we’re all in. Together, we’re paving a path to long-term success. I am excited about the opportunity to be GI-focused and to bring exciting new therapies to our trusted GI community.”. Everyone at Ironwood is a true owner of the company. OUR BOARD OF DIRECTORS We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. For more information, including how to adjust your cookie settings, please see our Cookie Policy.By continuing to navigate our website, you consent to the use of cookies. IRONWOOD PHARMACEUTICALS, INC. – The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a OPEN PAYMENTS AND TRANSPARENCY The CMS Open Payments Customer Support Line Help Desk is also accessible via email at openpayments@cms.hhs.gov and via phone at 1-855-326-8366 (Monday through Friday, from 8:30 a.m. to 7:30 p.m. (ET), excluding federal holidays). Our Values. IRONWOOD PHARMACEUTICALS, INC. Investor Contacts. Investor Emails Alerts. RSS Feeds. Home › Investors › Events & Presentations. NASDAQ: IRWD 12.48+0.05 0.40% Volume: 116,678 May 21, 2021 09:45 AM Pricing delayed by 20 minutes Click to learn more.TERMS OF USE
indemnification. you agree to indemnify and hold harmless ironwood, its affiliates, agents, vendors and licensors, and their respective employees, owners and representatives against any and all claims, of whatever nature, that arise out of any breach by you of this agreement or your use of this site, to the fullest extent allowed by law. IRONWOOD PHARMACEUTICALS, INC. Ironwood Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Ironwood Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Ironwood Pharmaceuticals, Inc. or its management. * Skip to main navigation * Skip to main content* Skip to Footer
__
* Investors
* Media
* Contact Us
* Our Company
* Our Values
* Our Executive Team * Our Board of Directors * Open Payments and Transparency* Our Product
* Discovery of Linaclotide* Our Pipeline
* Partnerships
* Patients
* Join Us
* Open Positions
* Internships, Co-ops and Fellowships * Things You Should Know* Our Company
* Our Values
* Our Executive Team * Our Board of Directors * Open Payments and Transparency* Our Product
* Discovery of Linaclotide* Our Pipeline
* Partnerships
* Patients
* Investors
* Events & Presentations * Corporate Governance * Financial Information* Stock Information
* Investor FAQ
* Press Releases
* Investor Contacts
* Join Us
* Open Positions
* Internships, Co-ops and Fellowships * Things You Should Know* Media
IRONWOOD IS A HEALTHCARE COMPANY DEDICATED TO MAKING A DIFFERENCE FOR PEOPLE LIVING WITH GASTROINTESTINAL (GI) DISEASESIRONWOODPHARMACEUTICALS
MEDIA RELEASES
May 26, 2021
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage StrengthMay 24, 2021
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week®(DDW)
Learn About Our PipelineView
Interested in Joining Our Team?View
Our Company
* Our Values
* Our Executive Team * Our Board of Directors * Open Payments and TransparencyOur Product
* Discovery of Linaclotide * Report a possible side effectOur Pipeline
Partnerships
Patients
Join Us
* Open Positions
* Internships, Co-ops and Fellowships * Things You Should KnowInvestors
* Events & Presentations * Corporate Governance * Financial Information* Stock Information
* Investor FAQ
* Press Releases
* Investor Contacts
Media
Contact Us
* Follow Us
* Privacy Policy
* Terms of Use
* California Privacy Policy* Site Map
* Contact Us
Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. Allrights reserved.
YOU ARE NOW LEAVING WWW.IRONWOODPHARMA.COM. This link will take you to a website to which our privacy policy does not apply. You are solely responsible for your interactions with thatwebsite.
* Continue
* Cancel
We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. For more information, including how to adjust your cookie settings, please seeour Cookie Policy
. By
continuing to navigate our website, you consent to the use ofcookies.Accept
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0